Background/Objectives: The prognosis of colorectal cancer (CRC) is mainly based on the clinical stage; however, CRC is considered a complex disease due to its molecular heterogeneity. The development of novel biomarkers to improve patients’ diagnosis and prognosis remains fundamental.Methods: A cohort of forty-nine CRC patients from the National Cancer Institute of Mexico was included to collect clinical and miRNA expression data. The expression of a group of miRNAs was compared between CRC and non-tumoral adjacent tissues. Prognosis assessment considering each miRNA expression was tested using Kaplan–Meier survival curves and Cox regressions. Statistical significance was defined asp≤ 0.05. Trial registration: Retrospective study No.2021/046.Results: miR-3065-5p and miR-26a-5p expression differed between non-tumoral adjacent and tumoral tissues (p= 0.02). In terms of overall survival (OS), patients with low expression of miR-3065-5p had a median OS of 70 months, while patients with high levels did not reach the median OS (p= 0.041). Male patients with low expression of this miRNA had an OS of 70 months, whereas patients with high levels did not reach the median OS (p= 0.050). Under uni-multivariate analysis, clinical stage (HR: 1.30, CI 1.23–2.30;p: 0.001) and low levels of miR-3065-5p (HR: 1.30, CI 1.23–2.30;p: 0.001) were determined as predictor factors of OS. To this end, we designed the “Prognosis miRNAs assessment in cancer” (PROMIR-C) algorithm, which integrated clinical features with miR-3065-5p expression levels.Conclusions: These findings support the clinical utility of miR-26a-5p and miR-3065-5p in the diagnosis and prognosis of CRC. PROMIR-C is a fundamental tool for clinicians in treatment decision-making, prognosis assessment, and outcome of CRC.
背景/目的：结直肠癌（CRC）的预后主要依据临床分期，但由于其分子异质性，CRC被认为是一种复杂的疾病。开发新型生物标志物以改善患者的诊断和预后仍然至关重要。 方法：本研究纳入了来自墨西哥国家癌症研究所的49例CRC患者队列，收集其临床数据和miRNA表达数据。比较了CRC组织与非肿瘤邻近组织中一组miRNA的表达水平。采用Kaplan-Meier生存曲线和Cox回归分析评估各miRNA表达对预后的影响。统计学显著性定义为p≤0.05。试验注册号：回顾性研究2021/046。 结果：miR-3065-5p和miR-26a-5p在非肿瘤邻近组织与肿瘤组织中的表达存在差异（p=0.02）。在总生存期（OS）方面，miR-3065-5p低表达患者的中位OS为70个月，而高表达患者未达到中位OS（p=0.041）。该miRNA低表达的男性患者OS为70个月，而高表达患者未达到中位OS（p=0.050）。单多变量分析显示，临床分期（HR: 1.30, CI 1.23–2.30; p: 0.001）和miR-3065-5p低表达（HR: 1.30, CI 1.23–2.30; p: 0.001）是OS的预测因素。为此，我们设计了"癌症预后miRNA评估"（PROMIR-C）算法，该算法整合了临床特征与miR-3065-5p表达水平。 结论：这些发现支持miR-26a-5p和miR-3065-5p在CRC诊断和预后中的临床应用价值。PROMIR-C是临床医生在治疗决策、预后评估和CRC结局判断中的重要工具。
miR-3065-5p and miR-26a-5p as Clinical Biomarkers in Colorectal Cancer: A Translational Study
肿瘤(癌症)患者之家